AGP Picks
View all

News on science and technology in Texas

Provided by AGP

Texas Technology Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Texas Technology Digest.

Press releases published on March 12, 2026

Broadcom Showcases Industry-Leading Solutions for Scaling AI Infrastructure at OFC 2026
­­Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Crane NXT Announces Appointment of Jeffrey Benck to Board of Directors
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Silvaco Reports Fourth Quarter and Full-Year 2025 Financial Results
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
ServiceTitan Announces Fiscal Fourth Quarter and Full Fiscal Year 2026 Financial Results
EverCommerce Announces Fourth Quarter and Full Year 2025 Financial Results
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Core Molding Technologies Announces $7,500,000 Stock Repurchase Program
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update 
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Share us

on your social networks:

Sign up for:

Texas Technology Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.